Ras neoantigens and uses thereof

A pharmaceutical composition comprising:

• (a) T cells comprising a population of T cells expressing a T cell receptor (TCR) that binds to a complex of (i) an MHC protein encoded by an HLA-C03:04 allele and (ii) an epitope with a sequence GACGVGKSA;
• (b) T cells comprising a population of T cells expressing a T cell receptor (TCR) that binds to a complex of (i) an MHC protein encoded by an HLA-C03:03 allele and (ii) an epitope with a sequence GAVGVGKSA;
• (c) antigen presenting cells (APCs) expressing an MHC protein encoded by an HLA-C03:04 allele, wherein the APCs comprise (i) a peptide having an epitope with a sequence GACGVGKSA or (ii) a polynucleotide encoding the peptide;
• or
• (d) APCs expressing an MEW protein encoded by an HLA-C03:03 allele, wherein the APCs comprise (i) a peptide having an epitope with a sequence GAVGVGKSA or (ii) a polynucleotide encoding the peptide.

A method of treating a subject with cancer comprising administering to the subject

• (a) a peptide,
• (b) a polynucleotide encoding the peptide,
• (c) antigen presenting cells (APCs) comprising (a) or (b), or
• (d) T cells stimulated with APCs comprising (a) or (b);
• wherein:
• (i) the peptide comprises an epitope with a sequence GACGVGKSA and the subject expresses a protein encoded by an HLA-C03:04 allele, or
• (ii) the peptide comprises an epitope with a sequence GAVGVGKSA and the subject expresses a protein encoded by an HLA-C03:03 allele.